Triazolopyridine compounds as PIM kinase inhibitors
US8987251B2 · kind B2 · utility
0Cited by
1References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2013 |
| Grant date | Mar 24, 2015 |
| Priority date | — |
| Expiry date | Oct 18, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I:in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.